LAUSR

Objective: To explore the significance of recombinant human growth hormone(rhGH) therapy in promoting the growth and development of children with idiopathic short stature (ISS). Methods: Medical records of 95 children with ISS, treated in our hospital from July 2019 to July 2020, were retrospectively selected and divided into two groups based on the received treatment. Of them, 41 patients received routine treatment (Group-I) and 54 patients received a combination of routine and rhGH treatment (Group-II). The levels of serum insulin-like growth factor-1 (IGF-1), bone age, growth velocity, height standard deviation score (Ht-SDS), and adverse reactions were compared and analyzed between the two groups. Results: After treatment, IGF-1, bone age, growth velocity, and Ht-SDS in Group-II were higher than those in Group-I (P < 0.05); After treatment, the incidence of adverse reactions in Group-II was 7.41%, which had no significant difference compared with 7.32% in Group-I (P > 0.05). Conclusion: In the treatment of children with Idiopathic Short Stature (ISS), the choice of rhGH can further improve the curative effect, promote the growth and development of children, without significant adverse reactions.